MENU
+Compare
BLTE
Stock ticker: NASDAQ
AS OF
Mar 28 closing price
Price
$66.70
Change
-$0.15 (-0.22%)
Capitalization
2.16B

BLTE Belite Bio Forecast, Technical & Fundamental Analysis

Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout... Show more

BLTE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for BLTE with price predictions
Mar 27, 2025

BLTE in upward trend: 10-day moving average broke above 50-day moving average on March 07, 2025

The 10-day moving average for BLTE crossed bullishly above the 50-day moving average on March 07, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 7 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

BLTE moved above its 50-day moving average on March 04, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BLTE advanced for three days, in of 176 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 138 cases where BLTE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The 10-day RSI Indicator for BLTE moved out of overbought territory on March 19, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 17 similar instances where the indicator moved out of overbought territory. In of the 17 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on March 24, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on BLTE as a result. In of 57 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for BLTE turned negative on March 25, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 24 similar instances when the indicator turned negative. In of the 24 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BLTE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

BLTE broke above its upper Bollinger Band on March 04, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BLTE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (14.771) is normal, around the industry mean (14.047). P/E Ratio (0.000) is within average values for comparable stocks, (66.086). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.907). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (239.969).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BLTE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
BLTE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

BLTE is expected to report earnings to rise 15.63% to -37 cents per share on May 07

Belite Bio BLTE Stock Earnings Reports
Q1'25
Est.
$-0.37
Q4'24
Est.
$-0.32
Q3'24
Beat
by $0.01
Q2'24
Missed
by $0.05
Q1'24
Beat
by $0.01
The last earnings report on March 17 showed earnings per share of -31 cents, meeting the estimate of -31 cents. With 17.21K shares outstanding, the current market capitalization sits at 2.16B.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
12750 High Bluff Drive
Phone
+1 858 246-6240
Employees
20
Web
https://www.belitebio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GSIEX29.12N/A
N/A
Goldman Sachs International Eq ESG Instl
LZUOX16.22N/A
N/A
Lazard US Equity Focus Open
MDVSX9.92N/A
N/A
MassMutual Diversified Value R5
FSGEX15.36N/A
N/A
Fidelity Series Global ex US Index
SMISX26.00-0.74
-2.77%
Invesco Summit R6

BLTE and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, BLTE has been loosely correlated with RAIN. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if BLTE jumps, then RAIN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BLTE
1D Price
Change %
BLTE100%
+2.51%
RAIN - BLTE
48%
Loosely correlated
-2.07%
ACOG - BLTE
24%
Poorly correlated
-3.80%
ELVN - BLTE
23%
Poorly correlated
+4.52%
TVTX - BLTE
23%
Poorly correlated
-2.02%
SAGE - BLTE
23%
Poorly correlated
+0.70%
More